ESMO 2016 | Next steps for niraparib for ovarian cancer following on from the ENGOT-OV16/NOVA trial
Sven Mahner, MD, PhD of the University Medical Center Hamburg-Eppendorf Hamburg, Germany talks about next steps for the ENGOT-OV16/NOVA Phase III trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (NCT01847274). Dr Mahner explains that usually the next step would be publication but in this case, the results were published in the New England Journal of Medicine while the results were presented at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark. The next big step is to give patients access to the drug as soon as possible. Further, they will also examine if niraparib can be moved further upfront, if it can be combined with other targeted drugs and if it can be used to avoid chemotherapy for certain patients with recurrent ovarian cancer.
Get great new content delivered to your inboxSign up